S
Shirley Lasch
Publications - 17
Citations - 3102
Shirley Lasch is an academic researcher. The author has contributed to research in topics: Parkinson's disease & Mutation (genetic algorithm). The author has an hindex of 15, co-authored 17 publications receiving 2241 citations.
Papers
More filters
Journal ArticleDOI
The Parkinson Progression Marker Initiative (PPMI)
Kenneth Marek,Danna Jennings,Shirley Lasch,Andrew Siderowf,Caroline M. Tanner,Tanya Simuni,Christopher S. Coffey,Karl Kieburtz,Emily Flagg,Sohini Chowdhury,Werner Poewe,Brit Mollenhauer,Todd Sherer,Mark Frasier,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Ying Zhang,Arthur W. Toga,Karen Crawford,Alison Ansbach,Pasquale De Blasio,Michele Piovella,John Q. Trojanowski,Les Shaw,Andrew B. Singleton,Keith A. Hawkins,Jamie L. Eberling,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David G. Standaert,Stephanie Guthrie,Robert A. Hauser,Holly Delgado,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Baochan Tran,James B. Leverenz,Marne Baca,Sam Frank,Cathi A. Thomas,Irene H. Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Elisabeth Lang,Holly A. Shill,Sanja Obradov,Hubert H. Fernandez,Adrienna Winters,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Melissa Gerstenhaber,David J. Brooks,Sophie Malloy,Paolo Barone,Katia Longo,Tom Comery,Bernard Ravina,Igor D. Grachev,Kim Gallagher,Michelle Collins,Katherine Widnell,Suzanne Ostrowizki,Paulo Fontoura,F. Hoffmann La-Roche,Tony W. Ho,Johan Luthman,Marcel P. van der Brug,Alastair D. Reith,Peggy Taylor +82 more
TL;DR: The Parkinson Progression Marker Initiative (PPMI) is a comprehensive observational, international, multi-center study designed to identify PD progression biomarkers both to improve understanding of disease etiology and course and to provide crucial tools to enhance the likelihood of success of PD modifying therapeutic trials.
Journal ArticleDOI
Association of Cerebrospinal Fluid β-Amyloid 1-42, T-tau, P-tau181, and α-Synuclein Levels With Clinical Features of Drug-Naive Patients With Early Parkinson Disease
Ju-Hee Kang,Ju-Hee Kang,David J. Irwin,Alice Chen-Plotkin,Andrew Siderowf,Chelsea Caspell,Christopher S. Coffey,Teresa Waligorska,Peggy Taylor,Sarah Pan,Mark Frasier,Kenneth Marek,Karl Kieburtz,Danna Jennings,Tanya Simuni,Caroline M. Tanner,Andrew B. Singleton,Arthur W. Toga,Sohini Chowdhury,Brit Mollenhauer,John Q. Trojanowski,Leslie M. Shaw,Shirley Lasch,Emily Flagg,Werner Poewe,Todd Sherer,Claire Meunier,Alice Rudolph,Cindy Casaceli,John Seibyl,Susan Mendick,Norbert Schuff,Liz Uribe,Jon W. Yankey,Karen Crawford,Alison Scutti,Paola Casalin,Giulia Malferrari,Keith A. Hawkins,David W. Russell,Laura Leary,Stewart A. Factor,Barbara Sommerfeld,Penelope Hogarth,Emily Pighetti,Karen Williams,David Standaert,Stephanie Guthrie,Robert A. Hauser,Joseph Jankovic,Christine Hunter,Matthew B. Stern,Abigail Darin,James B. Leverenz,Marne Baca,Sam Frank,Cathi-Ann Thomas,Irene Richard,Cheryl Deeley,Linda Rees,Fabienne Sprenger,Wolfgang Oertel,Diana Willeke,Holly A. Shill,Hubert H. Fernandez,Jennifer Mule,Daniela Berg,Katharina Gauss,Douglas Galasko,Deborah Fontaine,Zoltan Mari,Arita McCoy,David Brooks,Bina Shah,Paolo Barone,Stuart Isaacson,Angela James,Alberto J. Espay,Kristy J. Espay,Dominic B. Rowe,Madelaine Ranola +80 more
TL;DR: It is found that measures of CSF Aβ1-42, T-t Tau, P-tau181, and α-synuclein have prognostic and diagnostic potential in early-stage PD.
Journal ArticleDOI
The Parkinson's progression markers initiative (PPMI): establishing a PD biomarker cohort
Kenneth Marek,Sohini Chowdhury,Andrew Siderowf,Shirley Lasch,Christopher S. Coffey,Chelsea Caspell-Garcia,Tanya Simuni,Danna Jennings,Caroline M. Tanner,John Q. Trojanowski,Leslie M. Shaw,John Seibyl,Norbert Schuff,Andrew B. Singleton,Karl Kieburtz,Arthur W. Toga,Brit Mollenhauer,Doug R. Galasko,Lana M. Chahine,Daniel Weintraub,Tatiana Foroud,Duygu Tosun-Turgut,Kathleen L. Poston,Vanessa Arnedo,Mark Frasier,Todd Sherer,Parkinson's Progression Markers Initiative +26 more
TL;DR: The Parkinson's Progression Markers Initiative (PPMI) is an observational, international study designed to establish biomarker‐defined cohorts and identify clinical, imaging, genetic, and biospecimen Parkinson's disease progression markers to accelerate disease‐modifying therapeutic trials.
Journal ArticleDOI
Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease
Daniel Weintraub,Tanya Simuni,Chelsea Caspell-Garcia,Christopher S. Coffey,Shirley Lasch,Andrew Siderowf,Dag Aarsland,Paolo Barone,David J. Burn,Lama M. Chahine,Jamie L. Eberling,Alberto J. Espay,Eric D. Foster,James B. Leverenz,Irene Litvan,Irene H. Richard,Matthew D. Troyer,Keith A. Hawkins +17 more
TL;DR: This study was undertaken to determine the prevalence and correlates of cognitive impairment and neuropsychiatric symptoms in early, untreated patients with Parkinson's disease.
Journal ArticleDOI
Impaired olfaction and other prodromal features in the Parkinson At-Risk Syndrome Study.
Andrew Siderowf,Danna Jennings,Shirley Eberly,David Oakes,Keith A. Hawkins,Albert Ascherio,Matthew B. Stern,Kenneth Marek,David W. Russell,Abby Fiocco,Candace Cotto,Kapil D. Sethi,Paula Jackson,Samuel Frank,Anna Hohler,Cathi A. Thomas,Raymond C. James,Tanya Simuni,Emily Borushko,M.B. Stern,Jacqueline Rick,Robert A. Hauser,Leyla Khavarian,Theresa McClain,Irene H. Richard,Cheryl Deely,Grace S. Liang,Liza Reys,Charles H. Adler,Amy Duffy,Rachel Saunders-Pullman,Marian L. Evatt,Linda McGinn,Eugene Lai,Shawna Johnson,Farah Atassi,Michael E. DeBakey,Indu Subramanian,Angelina Gratiano,Kathryn A. Chung,Brenna M. Lobb,Susan O'Conner,Maria R. Albelo,Carolyn Cioffi,Allison Gadoury,Brian Howard,Valerie Iannucci,Shirley Lasch,Susan Mendick,Donna Miles,Katrina Miles,Emily Virden,Gary Wisniewski +52 more
TL;DR: Assessment of hyposmic subjects using more specific markers for degeneration, such as dopamine transporter imaging, will evaluate whether combining hyposmia and other nonmotor features is useful in assessing the risk of future neurodegeneration.